This editorial commentary examines the growing crisis of antimicrobial resistance, reviews the current antibiotic pipeline, and discusses novel therapeutic approaches including phage therapy and AI-driven drug discovery.

This pooled analysis reports 7-year cardiovascular outcomes from the open-label extension phases of the FOURIER and ODYSSEY OUTCOMES trials of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease.

This editorial commentary discusses the expanding therapeutic landscape of GLP-1 receptor agonists, from diabetes management to cardiovascular risk reduction, obesity treatment, and emerging neurological applications.

This phase 2b trial compares the efficacy of psilocybin-assisted therapy with escitalopram in adults with treatment-resistant major depressive disorder over 12 weeks.

This systematic review evaluates the efficacy and safety of semaglutide 2.4 mg for weight management in adults with obesity, synthesizing evidence from the STEP clinical trial program.

This meta-analysis of 12 randomized controlled trials evaluates the effects of SGLT2 inhibitors on cardiovascular death and heart failure hospitalization across the spectrum of ejection fraction.

This updated meta-analysis of 38 randomized controlled trials involving 149,051 participants evaluates the effect of omega-3 fatty acid supplementation on all-cause mortality and cause-specific mortality.

This multicenter randomized trial compares the efficacy of standardized, encapsulated fecal microbiota transplantation with fidaxomicin for the prevention of recurrent Clostridioides difficile infection after an initial episode of recurrence.